AFFILIATIONS
1 Department of Hematology, State Key Laboratory for Complex, Severe, and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2 National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin Institutes of Health Science, Tianjin, China
3 Department of Hematology, State Key Laboratory for Complex, Severe, and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
4 Affiliated Hospital of Chengde Medical University, Chengde, China
5 Henan Cancer Hospital/ The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
6 People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China
7 The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
8 Binzhou Medical University Hospital, Binzhou, China
9 The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
10 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
11 Chenzhou First People's Hospital, Chenzhou, China
12 Nanfang Hospital, Southern Medical University, Guangzhou, China
13 Jiangxi Provincial People's Hospital, Nanchang, China
14 The First Affiliated Hospital and the College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China
15 Xiangyang Central Hospital, Xiangyang, China
16 Affiliated Hospital of Guangdong Medical University, Zhanjiang, China
17 Hainan General Hospital, Haikou, China
18 Jiangxi Clinical Research Center for Hematologic Disease, Jiangxi Provincial Key Laboratory of Hematological Diseases, The First Affiliated Hospital, Jiangxi Medical College, Nanchang, China
19 Shaanxi Provincial People's Hospital, Xi'an, China
20 The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
21 Yantai Yuhuangding Hospital, Yantai, China
22 Harbin the First Hospital, Harbin, China
23 The Second Hospital of Lanzhou University, Lanzhou, China
24 The Affiliated Hospital of Southwest Medical University, Luzhou, China
25 The Third Xiangya Hospital of Central South University, Changsha, China
26 Xiangya Hospital of Central South University, Changsha, China
27 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
28 Shenzhen Second People's Hospital, Shenzhen, China
29 Second Affiliated Hospital of Kunming Medical University, Kunming, China
30 The Fifth Affiliated Hospital of Anhui Medical University, Fuyang, China
31 Jinshan Hospital of Fudan University, Shanghai, China
32 Qinghai Provincial People's Hospital, Xining, China
33 Fujian Medical University Union Hospital, Fuzhou, China
34 The First Affiliated Hospital of Guilin Medical University, Guilin, China
35 Affiliated Hospital of Nantong University, Nantong, China
36 Xinxiang Central Hospital, Xinxiang, China
37 Heping Hospital Affiliated to Changzhi Medical College, Changzhi, China
38 The First People's Hospital of Changde City, Changde, China
39 Affiliated Hospital of Hebei University, Baoding, China
40 HUTCHMED, Shanghai, China
41 HUTCHMED, Shanghai, China
42 HUTCHMED, Shanghai, China
43 HUTCHMED, Shanghai, China
44 HUTCHMED, Shanghai, China
45 The Second Hospital of Lanzhou University, Lanzhou, China
46 National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin Institutes of Health Science, Tianjin, China
ABSTRACT
Introduction: Warm autoimmune hemolytic anemia (wAIHA) is a potentially life-threatening autoimmune disease characterized by IgG-mediated red blood cell destruction, primarily through FcγR-dependent splenic macrophage phagocytosis. Currently, no targeted therapies are approved globally. While rituximab is widely used off-label in wAIHA, the treatment is associated with delayed onset of action and high relapse rates. Sovleplenib is a novel, oral spleen tyrosine kinase (SYK) inhibitor (SYK being a key regulator of FcγR signaling) that demonstrated clinically meaningful efficacy in the ESLIM-02 (NCT05535933) study (Zhang F, et al. EHA Library 2026) in patients (pts) with wAIHA who had received at least one prior glucocorticoid treatment. Here, we report the subgroup analysis results of ESLIM-02 in pts with prior rituximab exposure.
Methods: As previously reported, the ESLIM-02 phase 3 study was conducted at 38 sites in China. Adult pts with wAIHA and prior inadequate response to at least one prior glucocorticoid treatment were randomized 1:1 to receive sovleplenib 300 mg or placebo once daily for 24 weeks.
The primary endpoint was durable response rate (hemoglobin [Hb] ≥100 g/L with ≥20 g/L increase from baseline at three consecutive assessments ≥7 days apart, unaffected by rescue therapy) during weeks 5-24. Durable response rate was analyzed by prior rituximab treatment as a pre-defined subgroup analysis. In rituximab-exposed pts, post-hoc analyses were performed for secondary endpoints, including overall response rate (Hb ≥100 g/L and with an increase of ≥20 g/L from baseline, unaffected by rescue therapy), change from baseline in Hb, use of rescue therapy, reduction / discontinuation of baseline concomitant wAIHA therapy, cumulative duration of response, changes from baseline in FACIT-Fatigue scores and hemolytic markers, and safety.
Results: A total of 90 pts were enrolled, of whom 39% had received prior rituximab treatment (sovleplenib: 16 [36%]; placebo: 19 [41%]). In the rituximab-exposed subgroup (n=16 vs n=19), baseline median Hb (82.0 g/L vs 87.0 g/L), the proportion of pts with concomitant wAIHA therapy (81% vs 79%), and the median baseline FACIT-Fatigue scores (32 vs 39) were well-balanced between treatment groups.
Sovleplenib achieved notably higher durable response rates compared with placebo (69% vs 16%, p=0.0022) and substantially greater median change from baseline in Hb level throughout treatment (24.3 g/L vs -1.0 g/L), with ≥2-fold higher improvement versus placebo at each visit.
Sovleplenib showed superiority across other efficacy endpoints: higher overall response rate (75% vs 21%, p=0.0022), reduced rescue therapy use rate (13% vs 47%, p<0.05), increased RBC transfusion-free rate during weeks 5-24 (100% vs 68%, p<0.05), and higher rate of reduction/discontinuation of baseline concomitant wAIHA therapy (54% vs 13%, p<0.05). Among overall responders (n=12 vs n=4), median cumulative duration of response was substantially longer with sovleplenib than placebo (19.6 weeks vs 6.0 weeks). Generally, sovleplenib showed greater improvements from baseline in both FACIT-Fatigue scores and hemolytic markers, compared with placebo.
The median treatment duration was 23.9 weeks with sovleplenib and 20 weeks with placebo; 12 (75%) and 6 (32%) pts received treatment for ≥24 weeks, respectively. Grade ≥3 treatment-emergent adverse events (TEAEs) occurred in 6 (38%) pts with sovleplenib and 10 (53%) pts with placebo, most commonly (≥10%) warm autoimmune hemolytic anemia (19% vs 37%) and upper respiratory tract infection (6% vs 16%). No TEAEs led to treatment discontinuation or death in the sovleplenib group.
Conclusions: Sovleplenib provided notable clinical benefit with an acceptable safety profile in pts with relapsed/refractory wAIHA who were exposed to rituximab, representing a valuable treatment option for this population.